Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years

作     者：Manuel Barreiro-de Acosta Aurelio Lorenzo Juan Enrique Dominguez-Muoz 

作者机构：Department of GastroenterologyUniversity Hospital of Santiago de CompostelaC/Choupanas/nE-15706-Santiago de CompostelaSpain 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2009年第15卷第30期

页      面：3814-3816页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Adalimumab Ulcerative colitis Mucosalhealing Maintenance treatment 

摘      要：Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC. We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years. Both patients received concomitant immunosuppressive treatment. Long term clinical remission and mucosal healing are described.